Longevity & AgingNine Tumor Reports Raise Safety Questions About Zolgensma Gene Therapy
Tumor reports after Zolgensma gene therapy are raising questions about long-term treatment safety. Novartis says it has received nine reports of tumors in children previously treated for spinal muscular atrophy, a genetic disease that damages nerve cells controlling movement. Two cases showed evidence that DNA delivered by the therapy had entered patients’ own DNA. That finding warrants investigation but does not, by itself, prove the treatment caused cancer. Both patients received treatment and remain under observation. The drug’s labeling already notes a theoretical tumor risk from this type of DNA insertion. Crucial details remain missing, including tumor types, timing, and the total number of treated patients. Families should discuss evolving safety guidance with their specialists rather than infer a cancer risk from report counts alone.
